Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $558
Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $558
古根海姆保持福泰製藥買入評級,將價格目標上調至558美元。
Guggenheim analyst Debjit Chattopadhyay maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $450 to $558.
古根海姆的分析師Debjit Chattopadhyay認爲福泰製藥(NASDAQ:VRTX)值得買入,並將目標價從450美元提高到558美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。